Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling

Abstract

Based on ibrutinib pharmacokinetics and potential sensitivity towards CYP3A4-mediated drug-drug interactions (DDIs), a physiologically based pharmacokinetic approach was developed to mechanistically describe DDI with various CYP3A4 perpetrators in healthy men under fasting conditions. These models were verified using clinical data for ketoconazole (strong CYP3A4 inhibitor) and used to prospectively predict and confirm the inducing effect of rifampin (strong CYP3A4 inducer); DDIs with mild (fluvoxamine, azithromycin) and moderate inhibitors (diltiazem, voriconazole, clarithromycin, itraconazole, erythromycin), and moderate (efavirenz) and strong CYP3A4 inducers (carbamazepine), were also predicted. Ketoconazole increased ibrutinib area under the curve (AUC) by 24-fold, while rifampin decreased ibrutinib AUC by 10-fold; coadministration of ibrutinib with strong inhibitors or inducers should be avoided. The ibrutinib dose should be reduced to 140 mg (quarter of maximal prescribed dose) when coadministered with moderate CYP3A4 inhibitors so that exposures remain within observed ranges at therapeutic doses. Thus, dose recommendations for CYP3A4 perpetrator use during ibrutinib treatment were developed and approved for labeling.

Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies

“…When considering the combination of ibrutinib and DOACs, it is also important to note that ibrutinib primarily undergoes CYP3A4‐mediated metabolism, and CYP3A4 inhibitors will increase ibrutinib exposure . Rivaroxaban and apixaban in particular undergo CYP3A4‐mediated metabolism (33% and 25%, respectively), whereas dabigatran and edoxaban do not .…”

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011–2017: Lessons Learned for Anticancer Drug Development

“…In this context, PBPK modeling and simulation can subsequently be used to predict lower‐risk scenarios (e.g., the effect of moderate inhibitors or inducers or intermediate metabolizers) and support labeling statements related to DDI risk. This approach was utilized successfully for small molecule drugs, such as cobimetinib and ibrutinib, the details of which have been previously published . However, at the current time, a PBPK modeling approach cannot be relied upon exclusively to assess clinical DDI risk.…”

Itraconazole Increases Ibrutinib Exposure 10‐Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug‐Drug Interaction

“…The antifungal agent itraconazole is a strong inhibitor of CYP3A4 with favorable tolerability and absorption properties compared with ketoconazole . However, there is only a physiologically‐based pharmacokinetic modeling‐based estimate of the influence of itraconazole on ibrutinib pharmacokinetics, and clinical data are lacking …”